Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Expected to Post Q1 2026 Earnings of $2.01 Per Share

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities research analysts at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Tuesday, April 23rd. Zacks Research analyst S. Ganoria now forecasts that the biotechnology company will post earnings per share of $2.01 for the quarter, down from their previous forecast of $2.09. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.13 per share.

SRPT has been the topic of a number of other research reports. Needham & Company LLC cut their price target on Sarepta Therapeutics from $169.00 to $166.00 and set a "buy" rating on the stock in a report on Thursday, February 29th. BMO Capital Markets assumed coverage on Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an "outperform" rating and a $170.00 price target on the stock. UBS Group lifted their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the stock a "buy" rating in a research report on Friday, March 1st. Wedbush reiterated an "outperform" rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Finally, Barclays lifted their price objective on shares of Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, February 29th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $158.38.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded up $7.13 during mid-day trading on Wednesday, reaching $124.25. 1,500,081 shares of the company's stock traded hands, compared to its average volume of 985,086. The business's 50-day moving average price is $126.18 and its 200-day moving average price is $110.31. The stock has a market capitalization of $11.67 billion, a P/E ratio of -20.30 and a beta of 0.94. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.45 and a current ratio of 3.95. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.50. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The business had revenue of $396.80 million during the quarter, compared to the consensus estimate of $387.18 million. During the same period last year, the firm earned ($1.24) earnings per share. The company's revenue for the quarter was up 53.6% compared to the same quarter last year.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the business's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at approximately $2,815,030. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of the company's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $123.25, for a total transaction of $1,848,750.00. Following the completion of the transaction, the director now owns 22,840 shares of the company's stock, valued at $2,815,030. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Bilal Arif sold 2,000 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $128.84, for a total transaction of $257,680.00. Following the transaction, the insider now directly owns 26,836 shares of the company's stock, valued at approximately $3,457,550.24. The disclosure for this sale can be found here. In the last 90 days, insiders sold 22,096 shares of company stock valued at $2,739,419. Insiders own 7.40% of the company's stock.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Securities Inc. bought a new stake in Sarepta Therapeutics during the fourth quarter worth about $26,000. Mather Group LLC. bought a new stake in Sarepta Therapeutics during the first quarter worth about $28,000. Montag A & Associates Inc. bought a new stake in Sarepta Therapeutics during the third quarter worth about $30,000. Cary Street Partners Investment Advisory LLC grew its stake in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company's stock worth $31,000 after buying an additional 154 shares during the last quarter. Finally, GAMMA Investing LLC grew its stake in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company's stock worth $42,000 after buying an additional 87 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.